贝达药业(300558.SZ)：BPI-452080片药物临床试验申请获得受理

智通财经11-20

智通财经APP讯，贝达药业(300558.SZ)公告，今日，公司收到国家药品监督管理局(简称“NMPA”)签发的《受理通知书》(受理号：CXHL2401263、CXHL2401264、CXHL2401265)，公司申报的BPI-452080片药物临床试验(简称“该临床试验”)申请已获得NMPA受理。据悉，BPI-452080是一个由公司自主研发的拥有完全自主知识产权的新分子实体化合物，是一种创新、...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2484162524?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-11-20 17:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2484162524","market":"hk","top_or_hot":-1,"title":"贝达药业(300558.SZ)：BPI-452080片药物临床试验申请获得受理","media":"智通财经","content":"<div>\n<p>智通财经APP讯，贝达药业(300558.SZ)公告，今日，公司收到国家药品监督管理局(简称“NMPA”)签发的《受理通知书》(受理号：CXHL2401263、CXHL2401264、CXHL2401265)，公司申报的BPI-452080片药物临床试验(简称“该临床试验”)申请已获得NMPA受理。据悉，BPI-452080是一个由公司自主研发的拥有完全自主知识产权的新分子实体化合物，是一种创新、...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1213484.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>贝达药业(300558.SZ)：BPI-452080片药物临床试验申请获得受理</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n贝达药业(300558.SZ)：BPI-452080片药物临床试验申请获得受理\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-20 17:30 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1213484.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，贝达药业(300558.SZ)公告，今日，公司收到国家药品监督管理局(简称“NMPA”)签发的《受理通知书》(受理号：CXHL2401263、CXHL2401264、CXHL2401265)，公司申报的BPI-452080片药物临床试验(简称“该临床试验”)申请已获得NMPA受理。据悉，BPI-452080是一个由公司自主研发的拥有完全自主知识产权的新分子实体化合物，是一种创新、...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1213484.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"300558","symbol_name":"贝达药业","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1213484.html","article_id":"2484162524","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2484162524","pubTimestamp":1732095003,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，贝达药业 公告，今日，公司收到国家药品监督管理局签发的《受理通知书》，公司申报的BPI-452080片药物临床试验申请已获得NMPA受理。据悉，BPI-452080是一个由公司自主研发的拥有完全自主知识产权的新分子实体化合物，是一种创新、口服的小分子HIF-2α抑制剂，拟用于vonHippel-Lindau综合征相关肿瘤和实体瘤。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"300558":"贝达药业","03347":"泰格医药","BK1576":"医药外包概念","BK1141":"生命科学工具和服务","BK1583":"高瓴概念","BK0060":"抗癌","BK0239":"医药制造"},"translate_title":"Betta Pharmaceuticals (300558. SZ): BPI-452080 tablets clinical trial application accepted","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300558":1,"03347":1},"content_text":"智通财经APP讯，贝达药业(300558.SZ)公告，今日，公司收到国家药品监督管理局(简称“NMPA”)签发的《受理通知书》(受理号：CXHL2401263、CXHL2401264、CXHL2401265)，公司申报的BPI-452080片药物临床试验(简称“该临床试验”)申请已获得NMPA受理。据悉，BPI-452080是一个由公司自主研发的拥有完全自主知识产权的新分子实体化合物，是一种创新、口服的小分子HIF-2α(低氧诱导因子2α，Hypoxia inducible factor-2α)抑制剂，拟用于vonHippel-Lindau(VHL)综合征相关肿瘤和实体瘤(包括但不限于肾癌、胰腺神经内分泌肿瘤、副神经节瘤/嗜铬细胞瘤等)。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2484162524"}